Meeting
2013 ASCO Annual Meeting
Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients not candidates for optimal primary surgery: Safety and effectivenes.
Authors
Vanessa Costa Miranda
Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil
Vanessa Costa Miranda , Angelo Bezerra de Sousa Fede , Carlos Henrique Dos Anjos , Juliana Ribeiro da Silva , Fernando Barbosa Sanchez , Lyvia Rodrigues da Silva Bessa , Jesus Paula Carvalho , Dr Elias Abdo Filho , Daniela Freitas , Laryssa Almeida Borges de Barros , Samantha Cabral Severino da Silva , Maria Del Pilar Estevez-Diz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5540)
DOI
10.1200/jco.2013.31.15_suppl.5540
Abstract #
5540
Poster Bd #
44D
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Laparoscopic versus laparotomic cytoreduction in patients with advanced ovarian cancer submitted to NACT: Evaluation of oncologic safety.
First Author: Giovanni Favero
First Author: Elena Ioana Braicu
Poster
2023 ASCO Annual Meeting
Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010).
First Author: Yi Jiang
Poster
2022 ASCO Annual Meeting
Validation of the integrated prediction model algorithm for outcome of cytoreduction in advanced ovarian cancer.
First Author: Sabrina Piedimonte